Cardio-oncology & otherGuideline or statement
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association
- Scientific statement
Recommendations
As issued by the authors
Deprescribing strategies include observing clinical cues and triggers, using validated deprescribing tools, engaging in shared decision-making, and leveraging the roles of all members of the health care team to address barriers to deprescribing
Deprescribing can apply to both CV and non-CV drugs, as both contribute to polypharmacy and poor outcomes associated with inappropriate prescribing in patients with CVD
Original publication
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association. Circulation. Published 8 July 2026. doi:10.1161/cir.0000000000001459
Summarised from the published abstract; every number is checked against it